APA (7th ed.) Citation

Subramani, B., Conway, P. J., Al-Khinji, A., Zhang, K., Pandey, R., & Mahadevan, D. (2024). A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma. Cancers, 16(24), 4257. https://doi.org/10.3390/cancers16244257

Chicago Style (17th ed.) Citation

Subramani, Baskaran, Patrick J. Conway, Aisha Al-Khinji, Kun Zhang, Ritu Pandey, and Daruka Mahadevan. "A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma." Cancers 16, no. 24 (2024): 4257. https://doi.org/10.3390/cancers16244257.

MLA (9th ed.) Citation

Subramani, Baskaran, et al. "A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma." Cancers, vol. 16, no. 24, 2024, p. 4257, https://doi.org/10.3390/cancers16244257.